Compare
Ocular Therapeutix, Inc vs Lexicon Pharmaceuticals, Inc. vs Nektar Therapeutics vs Gossamer Bio, Inc.
| Latest fiscal year | Ocular Therapeutix, Inc OCUL | Lexicon Pharmaceuticals, Inc. LXRX | Nektar Therapeutics NKTR | Gossamer Bio, Inc. GOSS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $51.95M | $49.80M | $55.23M | $48.47M |
| Revenue growth (YoY) | -18.5% | +60.2% | -43.9% | -57.7% |
| Gross margin | 87.3% (computed) | n/a | n/a | n/a |
| Operating margin | -519.8% | -98.2% | -253.7% | -352.2% |
| Net margin | -511.9% | -101.1% | -297.1% | -351.5% |
| Net income | -$265.94M | -$50.34M | -$164.08M | -$170.37M |
| EPS (Diluted) | -$1.42 | -$0.14 | -$9.73 | -$0.75 |
| Operating cash flow | -$204.88M | -$67.85M | -$208.51M | -$171.27M |
| Free cash flow | -$216.89M | -$67.85M | -$208.68M | -$171.34M |
| Cash & equivalents | $737.06M | $34.33M | $15.12M | $37.73M |
| Total assets | $808.06M | $184.99M | $280.41M | $172.25M |
| Total liabilities | $153.75M | $77.45M | $190.57M | $295.01M |
| Shareholders' equity | $654.31M | $107.54M | $89.83M | -$122.76M |
| Return on year-end equity | -40.6% | -46.8% | -182.6% | n/a |
| Shares outstanding | 215.93M | 365.85M | 20.38M | 233.68M |
Revenue, most recent five fiscal years
| Fiscal year | Ocular Therapeutix, Inc | Lexicon Pharmaceuticals, Inc. | Nektar Therapeutics | Gossamer Bio, Inc. |
|---|---|---|---|---|
| Latest | $51.95M Ended 2025-12-31 | $49.80M Ended 2025-12-31 | $55.23M Ended 2025-12-31 | $48.47M Ended 2025-12-31 |
| 1 year earlier | $63.72M Ended 2024-12-31 | $31.08M Ended 2024-12-31 | $98.43M Ended 2024-12-31 | $114.70M Ended 2024-12-31 |
| 2 years earlier | $58.44M Ended 2023-12-31 | $1.20M Ended 2023-12-31 | $90.12M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $51.49M Ended 2022-12-31 | $139.0K Ended 2022-12-31 | $92.06M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | $43.52M Ended 2021-12-31 | $298.0K Ended 2021-12-31 | $101.91M Ended 2021-12-31 | n/a |